Spotting TED and treating early can benefit patients and may reduce the impact of the disease
TED is not a “watch and wait” disease—delaying diagnosis can impact timely treatment and patients' daily lives1-4
-
TED is a progressive autoimmune disease with debilitating visible and nonvisible signs and symptoms1,5-7
-
As the disease progresses, patients may notice worsening or additional symptoms that can create an ever-increasing burden of disease8
-
It can take some patients anywhere from 2 to nearly 5 years to get a TED diagnosis9
Use the TED mnemonic tool to spot the disease sooner
The TED mnemonic tool below breaks down a differential diagnosis in 4 easy-to-remember steps.
-
TED can have a significant impact on a patient’s emotional well-being, making them feel self-conscious8,10
-
If you suspect a patient has TED, it’s important to ask how they feel about themselves
-
Proptosis is 1 of the more common signs of TED1
-
Conduct an annual exam to screen for proptosis and other TED signs and symptoms
-
TED can cause a wide range of ocular symptoms, including visible and nonvisible signs and symptoms6,7
-
Screen your patients for all ocular symptoms of TED
-
TED patients often have a history of autoimmune thyroid conditions, like Graves’ disease3
-
If your patient has a thyroid disorder, screen for TED
Download the Patient Intake Form to help evaluate suspected TED patients or to assess the full impact of TED on their quality of life.
If you SPOT 2 or more of these signs or symptoms, download the mnemonic tool and consider TED as part of your differential diagnosis.
- Barrio-Barrio J, Sabater AL, Bonet-Farriol E, Velázquez-Villoria Á, Galofré JC. Graves’ ophthalmopathy: VISA versus EUGOGO classification, assessment, and management. J Ophthalmol. 2015;2015:249125.
- Bothun ED, Scheurer RA, Harrison AR, Lee MS. Update on Thyroid Eye Disease and management. Clin Ophthalmol. 2009;3:543-551.
- Burch HB, Perros P, Bednarczuk T, et al. Management of Thyroid Eye Disease: a consensus statement by the American Thyroid Association and the European Thyroid Association. Thyroid. 2022;32(12):1-32.
- Wang Y, Sharma A, Padnick-Silver L, et al. Physician-perceived impact of thyroid eye disease on patient quality of life in the United States. Ophthalmol Ther. 2021;10(1):75-87.
- Wang Y, Patel A, Douglas RS. Thyroid Eye Disease: how a novel therapy may change the treatment paradigm. Ther Clin Risk Manag. 2019;15:1305-1318.
- Bahn RS. Graves’ ophthalmopathy. N Engl J Med. 2010;362(8):726-738.
- Thyroid Eye Disease. National Organization for Rare Disorders. 2020. Accessed December 8, 2022. https://rarediseases.org/rare-diseases/thyroid-eye-disease
- Cockerham KP, Padnick-Silver L, Stuertz N, Francis-Sedlak L, Holt RJ. Quality of life in patients with chronic Thyroid Eye Disease in the United States. Ophthalmol Ther. 2021;10:975-987.
- Data on File. Horizon, April 2020.
- Smith TJ, Hegedüs L, Lesser I, Perros P, Dorris K, Kinrade M, Troy-Ott P, Wuerth L, Nori M. How patients experience thyroid eye disease. Front Endocrinol (Lausanne). 2023 Nov 9;14:1283374.
Receive the latest news and updates about Thyroid Eye Disease (TED).
Receive the latest news and updates about Thyroid Eye Disease (TED).